Managers / Q2 2019 · view latest →
SYQUANT CAPITAL SAS
CIK 0001766392 · 25 AVENUE KLEBER, PARIS, I0, 75116 · 0033142569307
Summary
Syquant Capital Sas reported $312M in U.S.-listed holdings across 14 positions for Q2 2019.
The portfolio is heavily concentrated: Red Hat alone accounts for 43.7% of reported value.
Compared with Q1 2019, the fund opened 10 new positions and exited 11.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 99.9% · $311M
- ADR · 0.1% · $456,000
Quarter-over-Quarter Changes full breakdown →
vs Q1 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| FDCFIRST DATA CORP NEW | NEW | +2.39M | 2.39M | +$65M | $65M |
| CELGCELGENE CORP | NEW | +379.9K | 379.9K | +$35M | $35M |
| MEDIDATA SOLUTIONS INC | NEW | +345.7K | 345.7K | +$31M | $31M |
| ARRAY BIOPHARMA INC | NEW | +417.1K | 417.1K | +$19M | $19M |
| CTRLCONTROL4 CORP | NEW | +296.8K | 296.8K | +$7M | $7M |
| GISGENERAL MLS INC | NEW | +65.0K | 65.0K | +$3M | $3M |
| OXYOCCIDENTAL PETE CORP | NEW | +49.5K | 49.5K | +$2M | $2M |
| VEONEER INCORPORATED | NEW | +115.0K | 115.0K | +$2M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RED HAT INC | COM | 43.70% | $136M | 725.4K |
| 2 | FDCFIRST DATA CORP NEWhistory → | COM CL A | 20.72% | $65M | 2.39M |
| 3 | CELGCELGENE CORPhistory → | COM | 11.27% | $35M | 379.9K |
| 4 | MEDIDATA SOLUTIONS INC | COM | 10.04% | $31M | 345.7K |
| 5 | ARRAY BIOPHARMA INC | COM | 6.20% | $19M | 417.1K |
| 6 | CTRLCONTROL4 CORPhistory → | COM | 2.26% | $7M | 296.8K |
| 7 | PACBPACIFIC BIOSCIENCES CALIF INhistory → | COM | 1.38% | $4M | 712.2K |
| 8 | GISGENERAL MLS INChistory → | COM | 1.10% | $3M | 65.0K |
| 9 | OXYOCCIDENTAL PETE CORP | COM | 0.80% | $2M | 49.5K |
| 10 | SPARK THERAPEUTICS INC | COM | 0.64% | $2M | 19.6K |
| 11 | VEONEER INCORPORATED | COM | 0.64% | $2M | 115.0K |
| 12 | US ECOLOGY INC | COM | 0.60% | $2M | 31.6K |
| 13 | DFRGDEL FRISCOS RESTAURANT GROUP | COM | 0.50% | $2M | 196.9K |
| 14 | GNFTYGENFIT S A | ADS | 0.15% | $456,000 | 23.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2026 | $447M | 38 | Jul 9, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q1 2026 | $640M | 40 | Apr 10, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $817M | 37 | Jan 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $348M | 17 | Oct 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $302M | 14 | Jul 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2025 | $141M | 14 | Apr 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $70M | 6 | Jan 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $27M | 5 | Oct 4, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $10M | 5 | Jul 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $64M | 6 | Apr 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $22M | 7 | Jan 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $255M | 9 | Oct 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $138M | 11 | Jul 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $43M | 7 | Apr 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $41M | 14 | Jan 17, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $165M | 25 | Oct 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $90M | 32 | Jul 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $195M | 35 | Apr 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $262M | 43 | Jan 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $164M | 42 | Oct 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $83M | 41 | Jul 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $386M | 53 | Apr 20, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $387M | 81 | Feb 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $196M | 62 | Oct 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $215M | 23 | Aug 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $407M | 18 | Apr 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $194M | 16 | Jan 8, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $365M | 17 | Oct 17, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $312M | 14 | Jul 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $258M | 15 | Apr 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $117M | 11 | Feb 4, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.